Drug Profile


Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Developer Transparency Life Sciences
  • Class Antihypertensives; Heart failure therapies; Small molecules
  • Mechanism of Action ACE inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Cardiovascular disorders
  • Preclinical Multiple sclerosis

Most Recent Events

  • 08 Sep 2014 Transparency Life Sciences receives SBIR grant from the National Center for Advancing Translational Sciences for lisinopril development in Multiple Sclerosis
  • 18 Dec 2012 Preclinical trials in Multiple sclerosis (adjunctive treatment) in USA (unspecified route)
  • 18 Dec 2012 The US FDA approves IND application for lisinopril as an adjunctive therapy in Multiple sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top